BLISSGVS vs MEDICAMEQ: Stock Comparison

Bliss GVS Pharma Limited vs Medicamen Biotech Limited

Live data: 2 July 2026, 4:08 PM IST • Source: NSE and company filings

Bliss GVS Pharma Limited is the larger company by market capitalisation. Bliss GVS Pharma Limited shows a higher ROCE and a higher net margin, while Medicamen Biotech Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Bliss GVS Pharma Limited and Medicamen Biotech Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BLISSGVS is more favourable on 6 of 13 scored metrics and MEDICAMEQ on 7These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BLISSGVS is the larger company
₹4,792 Cr vs ₹336 Cr
P/E Ratio
MEDICAMEQ has a lower P/E
32.07x vs 38.27x
P/B Ratio
MEDICAMEQ has a lower P/B
1.12x vs 4.14x
EPS
BLISSGVS has higher earnings per share
₹11.99 vs ₹7.21
Dividend Yield
MEDICAMEQ has a higher dividend yield
0.41% vs 0.19%
Revenue Growth (TTM YoY)
MEDICAMEQ has faster revenue growth
80.2% vs 29.8%
EPS Growth (TTM YoY)
BLISSGVS has faster EPS growth
124.7% vs 44.7%
Qtr Sales Growth
MEDICAMEQ has stronger quarterly sales growth
105% vs 13%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBLISSGVSMEDICAMEQ
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBLISSGVSMEDICAMEQ
Live Price₹527.1₹247.2
Day Change0.68%-0.68%
Volume3.93 L11,244
52-Week High₹553₹447.65
52-Week Low₹118₹212.4
Distance from 52W High-4.68%-44.78%

Valuation

MetricBLISSGVSMEDICAMEQ
Market Cap₹4,792 Cr₹336 Cr
P/E Ratio38.27x32.07x
P/B Ratio4.14x1.12x
EPS₹11.99₹7.21
Book Value₹107.21₹234.32
Dividend Yield0.19%0.41%

Growth

MetricBLISSGVSMEDICAMEQ
Revenue Growth (TTM YoY)29.8%80.2%
EPS Growth (TTM YoY)124.7%44.7%
Qtr Sales Growth13%105%
Qtr Profit Growth108%59.5%

Profitability & Leverage

MetricBLISSGVSMEDICAMEQ
ROE0%3.95%
ROCE11.7%5.43%
Net Margin13.93%5.21%
Operating Margin12.82%9.91%
Debt to Equity1.77x0.17x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricBLISSGVSMEDICAMEQ
Promoter Holding35.36%40.46%
FII Holding10.45% 4.09 pp0.07% 0.03 pp
DII Holding5.04% 0.74 pp0.4% 0.4 pp
Public Holding49.15% 4.83 pp59.02% 0.37 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Bliss GVS Pharma Limited and Medicamen Biotech Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.